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Abstract: 
Over several millennia, substances have been applied to the skin for treatment of 
pain. Some ingredients are in current use; others have been discontinued. 
Mechanisms of action include interactions with nociceptive neural networks and 
inflammatory processes. Substances must penetrate the stratum corneum 
barrier and vehicles that enhance penetration have been developed. Topical 
drugs with links to the past include menthol, capsaicin, some opioids, local 
anaesthetic agents and non-steroidal anti-inflammatory drugs. Mandragora is 
also described as an example of a herbal remedy that has been discontinued due 
to its toxicity. The future for topical drugs is promising, with the advent of new 
drugs tailored for specific pain mechanisms and the development of both 
penetration enhancers and sterile preparation methods.  
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Introduction 
Over several millennia, substances have been applied externally for painful 
conditions but with variable success. In modern times, the mode of action of 
these ancient remedies has become clearer. Our Neolithic ancestors most 
probably used herbal remedies but records only appeared with the advent of 
cuneiform writing on clay tablets by the Sumerians (Third dynasty of Ur, c.3100 
BCE)[1, 2], and later by the Egyptians writing on papyrus (Kahun c.1900 BCE and 
Ebers papyri c.1600 BCE).[3, 4] Pharmacopoeias of “bush medicines”, including 
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analgesic applications may, however, have been in existence for much longer. 
Indigenous cultures have existed in Australia dating back at least 40,000 
years.[5, 6] Recipes were initially passed on by oral tradition [7], but only 
appeared in the literature in recent times.[8] Similar ancient traditions of topical 
application for medicinal purposes can be found in Persian, Chinese, Indian, 
Central and South American cultures.[9] The use of herbal preparations 
continues to this day [10-12] and it is suggested that approximately 25% of 
modern medications are developed from plants. More than 85,000 plant species 
have been documented for medical use globally and many of them used 
topically.[13] This review will examine a number of substances, often with 
herbal ancestries, which have been applied topically over the past five thousand 
years. Some of these substances are still in use for the treatment of pain. Others, 
such as the topical application of Sciatica Cresses, listed in Culpepper’s Herbal for 
the treatment of sciatica, are confined to history and, thankfully, are no longer in 
use.  
 “The leaves but especially the root, taken fresh in summer time, beaten or made 
into a poultice or salve with old hog's grease, and applied to the places pained with 
the sciatica, to continue thereon four hours if it be on a man, and two hours on a 
woman; the place afterwards bathed with wine and oil mixed together, and then 
wrapped with wool or skins, after they have sweat a little will assuredly cure not 
only the same disease in hips, huckle-bone, or other of the joints, as gout in the 
hands or feet, but all other old griefs of the head, (as inveterate rheums) and other 
parts of the body that are hard to be cured. And if of the former griefs any parts 
remain, the same medicine after twenty days, is to be applied again.” [14] 
 
Mechanisms for Topical Analgesia  
Anatomy of nociception: A dense network of nerve fibres that runs along the 
dermal-epidermal junction, supplies strands that project through the epidermis 
almost to the skin surface. These nerve fibres are ideally positioned to detect 
potential sources of injury to the skin. When activated, they signal pain – often 
described as a sharp stabbing sensation or a burning ache.  They also coordinate 
an inflammatory response, initiated by release of vasoactive neuropeptides from 
the nerve terminals in the skin. Below we describe effects of the local 
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environment on nociceptive signalling, both under normal conditions and in 
inflammatory states and neuropathic pain. We also suggest possible mechanisms 
of analgesia for topically applied drugs. 
 Illustration: Normal Human Skin 
Propagation of nociception: Nociceptive sensations are detected by slowly-
conducting unmyelinated C-fibres and faster-conducting myelinated A-fibres, 
ranging in size from thinly myelinated A-delta fibres through to thicker, more 
heavily myelinated A-beta fibres.[15] The faster-conducting A-fibres lose their 
myelin sheath in the dermis, terminating as free nerve endings.[16] These nerve 
endings are exquisitely sensitive to chemical and thermal disturbances in the 
surrounding extracellular fluid. The subsequent propagation of neural impulses 
involves sequential opening of voltage-gated ion channels that permit passage of 
sodium, potassium, chloride and calcium through the neural membrane. In 
addition, many other ligand-gated channels regulate neural excitability (such as 
acid-sensing ion channels, transient receptor potential channels, and 
hyperpolarization-activated cyclic nucleotide-gated channels).[17] These 
mechanisms make neurons particularly sensitive to minor perturbations in their 
local environment and also provide many targets for topical drug manipulation.   
The inflammatory milieu: After injury to the skin, sensory transduction and 
signalling is modulated by a plethora of receptors that respond to substances 
released from the bloodstream, from injured tissue, from resident cells such as 
fibroblasts, keratinocytes, Langerhans cells and mast cells, and from immune 
cells recruited to the site of injury. Together, these substances produce a milieu 
containing, among other ingredients, hydrogen ions, prostaglandins, cytokines, 
growth factors, noradrenaline, glutamate, bradykinin, serotonin, histamine and 
adenosine.[18] This inflammatory milieu can both directly activate and sensitize 
nerve endings to stimulation by acting on ion channels (for example hydrogen 
ions that operate on acid-sensing ion channels) or by altering second-messenger 
systems (by acting on G-protein-coupled metabotropic receptors) such as α-
adrenoceptors). Externally applied topical drugs that modify this milieu or its 
targets can therefore act directly to reduce pain and inflammation. 
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Signal transduction: Sensory afferents interact with cutaneous cells that not only 
provide physical and trophic support but also contribute to signal transduction. 
For example, keratinocytes produce many of the receptors and transmitters 
expressed by neurons and, by this means, can communicate with neurons in a 
paracrine manner.[19, 20] This is important after nerve and tissue injury. For 
example, after limb fracture, neuropeptides and noradrenaline released from 
nerve terminals in the skin activate receptors on the surface of keratinocytes 
which, in turn, secrete high levels of inflammatory cytokines and nerve growth 
factor.[21, 22] These agents degranulate mast cells and sensitize cutaneous 
nociceptive neurons, thereby contributing to pain.[23] Topical drugs that 
penetrate the stratum corneum can act directly on this keratinocyte layer, 
possibly modifying its function. 
Receptor targets for analgesia: Some of the excitatory receptors expressed on 
peripheral nerve fibres provide useful targets for analgesia. For example, the 
capsaicin receptor (vanilloid receptor 1) is a member of the transient receptor 
potential (TRP) family of receptors and is expressed on polymodal 
nociceptors.[24] Occupancy of this receptor or activation by heat or hydrogen 
ions, triggers sodium and calcium ion influx, generates action potentials and 
results in burning pain. Excessive influx of calcium ions can, however, evoke 
desensitization, which potentially is useful in pain management. Another TRP 
receptor, TRPM8 (the menthol receptor), is expressed both on cold-specific A-
delta fibres and on cold-sensitive nociceptors.[25, 26] Low concentrations of 
menthol appear to primarily activate cold-specific fibres whereas higher 
concentrations activate nociceptors as well.[27] Like the capsaicin receptor, 
excessive influx of calcium ions into these cold-sensitive nociceptors is 
associated with desensitization and analgesia.[28] 
Although many receptors exert excitatory effects on neural activity, others 
inhibit neural excitability and discharge (for example, μ-opioid receptors).[29] 
Under normal conditions, the opioid receptors are separated from agents in the 
extracellular fluid by the perineurium, an impermeable sheath with tight cellular 
junctions that enclose bundles of nerve fibres. This sheath, however, becomes 
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porous during inflammation, thereby increasing access to protected receptors 
for endogenous and topically applied opioids.[30] 
The effects of chronic inflammation: The receptor and ion-channel profile alters 
dramatically during chronic inflammation and on nerve fibres that survive 
peripheral nerve injury. For example, inflammation triggers an increase in 
expression of glutamate receptors on nociceptive fibres [31, 32], thereby 
providing a target for ketamine, a glutamate (N-methyl-D-aspartate: NMDA) 
receptor antagonist. Similarly, an up-regulation of purinergic (P2X3) receptors 
after peripheral nerve injury profoundly influences neural excitability [33], in 
part via interaction with α1-adrenoceptors.[34, 35] An increase in the expression 
of α1-adrenoceptors on nerve fibres that survive partial nerve injury may also 
contribute to sympathetically maintained pain.[36, 37] 
Ion channels as further targets for analgesia: Changes in the function or 
expression of ion channels in inflammatory and neuropathic pain conditions may 
also mediate pain. For example, an up-regulation of NaV1.7 channels during 
inflammation and in rare hereditary pain disorders increases nociceptor 
excitability and impulse generation.[17] Local anaesthetic agents such as 
lidocaine inhibit pain and hyperalgesia partly by acting in a non-selective 
manner on voltage-gated sodium channels, including NaV1.7.[38, 39]  
 
Penetrating the Stratum Corneum  
The stratum corneum, the outermost layer of the skin, provides a barrier to 
noxious chemicals, potential infective agents, physical insults and solar radiation 
from the outside world that is protective for the organism. The layer protects 
against water loss but also presents a physical barrier to the ingress of topical 
and transdermal drugs. The stratum consists of multiple layers of dead hydrated 
corneocytes arranged in interdigitating layers that are surrounded by a lipid 
matrix comprising approximately 20% by volume.[40] The microanatomy has 
been described as a “brick-and-mortar” structure.[41, 42] Illustration 
It is not a perfectly uniform surface, varying in thickness at different parts of the 
body with the thickest layer on the soles of the feet. It is also perforated by hair 
follicles and sweat glands that can passively assist in the ingress of drugs from 
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the exterior. The skin is a complex structure as unwanted influences that cannot 
be physically kept on the exterior are subsequently neutralised and attacked by 
the immune system or degraded by enzymatic reactions.[40] 
Various techniques are employed to improve the penetration of drugs through 
the outer layers of the skin. These include physical formulation and delivery 
methods. Physical methods include low frequency ultrasound, which disturbs 
the lipid matrix, radiofrequency energy formation of microchannels or 
electrophoretic assisted penetration. Even removal of the outer horny layer can 
be employed using chemical peels and dermabrasion.[43] Formulation 
techniques are the most commonly applied methods for enhanced penetration of 
drugs. The barrier to the ingress of drugs is reversibly reduced by agents, such as 
the lipid disrupting aprotic solvent dimethylsulphoxide (DMSO) [44] and the 
liposome, pleuronic lecithin organogel (PLO).[45, 46] Liposomes have been 
extensively studied since their discovery in the 1960s.[47] They comprise a lipid 
bilayer with the hydrophobic chains of the lipids forming the bilayer and the 
polar head groups of the lipids orientated towards the extra vesicular solution 
and the inner cavity.[48] Liposomes help localise topical drugs at their desired 
site of action or improve the penetration of transdermal drugs into the systemic 
circulation without causing skin irritation or harm.[49-52] Other proprietary 
liposomal preparations include Lipoderm® and Vanpen® that have the capacity 
to deliver multiple drug combinations through the skin.[53-55] 
Despite the apparent harmless nature of topical applications, contact dermatitis 
can occur after the application of topical drugs or their vehicle components.[56] 
There can be irritant and allergic contact dermatitis or contact urticarial. Patch 
testing is used to ascertain the culprit allergen.[57] 
At this point, the distinction between topical and transdermal should be 
emphasised. There are several effective transdermal preparations such as 
transdermal fentanyl and buprenorphine, whereby the active ingredient gains 
access to the systemic circulation but by the transdermal route. Topical 
applications, however, such as the application of a lidocaine patch for post 
herpetic neuralgia, reduce nociception by local skin mechanisms but achieve 
minimal systemic levels. Although neuropathic pain states can be improved by 
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achieving systemic levels of lidocaine, this is not the main aim of this topical 
application. 
 
Historical Use of Topical Drugs 
There have been a number of reviews of the use of topical agents, in particular in 
the management of neuropathic pain.[58-62] The size of this review precludes 
an exhaustive coverage of this topic. The reviews by Zur, Sawynok, Argoff and 
others [58-62] take a wider view of current topical agents than is possible in this 
paper. This review has included topical agents with historical links and current 
agents with a significant background literature. A few substances have ancient 
traditions and some of particular interest have been selected for discussion. 
Some agents have been employed over many centuries but have disappeared 
from clinical use, while others such as amitriptyline, clonidine and ketamine are 
the creation of modern times.  
 
Menthol: The use of menthol stretches back into antiquity. It is a naturally 
occurring plant extract from several members of the plant genus Mentha (Mint) 
[63] but has been chemically synthesised in modern times. Menthol features in 
the Ebers papyrus (1550 BCE) as a remedy for stomach ailments [4] and there 
are claims of its cultivation for medicinal use in Japan over 2000 years ago.[63] 
Known in ancient Greece, the herb is named after the mythical beauty Minthe. 
The pungent sweet smelling mint was used in hospitality such as the fermented 
barley drink called the kykeon and in funerary rites.[64] Menthol is also included 
amongst a number of valuable herbs in the biblical indictment of the Pharisees 
(Luke 11:42). Peppermint appears in the London Pharmacopoeia in 1721 and 
menthol, the active ingredient, was first isolated as a compound by the Dutch 
botanist Gambius in 1771.[65] 
Menthol (also known as mint camphor) is experiencing a renaissance as a topical 
analgesic agent. As well as providing a subjective cooling effect, it acts as a weak 
opioid agonist and weak sodium channel blocker.[66, 67] It is used in 
dermatology as an antipruritic agent, as a food additive in chewing gum and to 
flavour toothpaste and cigarette smoke. Menthol is a cyclic terpene alcohol 
acting on the transient receptor potential melastatin 8 receptor (TRPM8), a low 
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temperature sensing receptor in the skin and mucosa, (8-28°C) [68, 69] where it 
imparts a cool sensation. Capsaicin, in contradistinction, was the first of the 
transient receptor potential family to be identified. Menthol has several desirable 
qualities as well as its actions as a topical antipruritic agent, including 
antibacterial and antifungal activity.[70] It has been shown to enhance 
penetration of the stratum corneum in both animal and human models [71] 
possibly through disruption of the lipid layer of the stratum corneum.[72] 
Topical menthol has analgesic actions that make it a beneficial inclusion in over-
the-counter pain relief applications. In low concentrations (<1%) menthol 
depresses cutaneous nociception and perhaps even desensitises nociceptive C 
fibres.[73] In high concentrations (>30% menthol can act as an irritant.[74, 75] 
As menthol acts on voltage-gated channels in neuronal structures, it also has a 
weak local anaesthetic effect.[76, 77] There are many possible uses for this 
topical agent, discussed in depth elsewhere.[78-81] Other substance acting on 
TRPM8 receptors include eucalyptol and the potent synthetic Icilin.[82] 
 
Capsaicinoids: Capsaicin is the principal active component in hot chilli peppers 
of the plant genus Capsicum, which have their origin in the Americas. Chilli 
peppers were probably cultivated as a dietary condiment dating back over 6000 
years.[83] Limited Mayan hieroglyphs (The Maya, circa 750BCE -1524 CE) have 
survived and have proved difficult to decipher as much written material was 
burnt in 1562. It is unknown if written descriptions of the medicinal use of chilli 
peppers exist from this period. Later, Aztec physicians in Central America may 
have used chilli pepper to treat painful conditions such as toothache.[84] Chilli 
pepper was probably transported to the Old World by Columbus and thence to 
Asia by Portuguese navigators in the 16th century.  
Other capsaicinoids known to antiquity include euphorbium whose active 
ingredient is the potent capsaicinoid resinifratoxin, extracted from the latex of 
Euphorbia resinifera.[85] The physician Euphorbius may have used 
resinifratoxin-containing salves to treat the arthritic pains of the Emperor 
Augustus 63 BCE -14 CE, but it was probably in use well before this time.[85] 
Previously used as an emetic and violent purgative, euphorbium has been 
employed as a rubefacient for painful joints.[86, 87] It was listed in 1578 for 
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treating toothache and more recently for intractable bone pain.[86] Topical plant 
extracts containing capsaicinoids such as Bhut jolokia, indigenous to Northeast 
India, are still in use to treat arthritic pains.[87] Bhut jolokia is recorded as being 
900.5 times as hot as Tabasco sauce.[88] One wonders what effect such a 
powerful capsaicinoid would have on the gastro-intestinal tract, if ingested.  
Capsaicin activates the transient receptor potential vanilloid receptor (TRPV1), 
an excitatory ion channel which is also activated by higher temperatures >43°C 
and is sensed as being hot.[24] Capsaicin has been extensively studied as a 
topical agent for the past three decades. As a low concentration, 0.025-0.075%, 
over-the-counter preparation (Zostrix), capsaicin has been prescribed for a 
number of conditions including post herpetic neuralgia. More recently it has also 
been marketed as an 8% patch (Qutenza) with effects lasting many weeks.[89] 
As a TRPV1 agonist, capsaicin induces a refractory period in nerve terminals 
expressing TRPV1 and in higher concentrations causes long term neuronal 
“defunctionalisation”.[90, 91] A single application of capsaicin 8% to the skin can 
diminish skin hypersensitivity in neuropathic pain states for periods as long as 
three months, reducing the issue of poor patient compliance with the weaker 
preparations that require multiple applications.[89, 92] The application of the 
8% patch can be intensely painful and is often applied under local anaesthesia. 
Targeting TRP channels on nociceptor neurons in the skin is an attractive 
strategy for pain control as it can modify the peripheral pain pathway.[93] The 
use of capsaicin preparations as a topical application for neuropathic pain states 
such as post herpetic neuralgia has been the subject of several Cochrane reviews 
of the supporting evidence. The author’s concluded that repeated application of 
low dose  (0.075%) capsaicin was without meaningful effect beyond placebo and 
that prior studies had not convincingly demonstrated efficacy. The use of low 
dose topical capsaicin commonly caused skin irritation leading to 
withdrawal.[94] The use of high dose capsaicin for neuropathic pain states 
including post herpetic neuralgia and HIV-neuropathy provided good relief of 
pain for about one patient in eight (NNT=8.8). It was also concluded that high 
dose capsaicin was probably less effective than gabapentin or pregabalin.[95]       
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Opioids: Opium obtained from Papaver somniferum was well known to the 
ancients and most probably was cultivated by the Sumerians (c. 3000 BCE) [96] 
and ancient Egyptians. Of particular historical interest is the use of transdermal 
patches of opioid in ancient Greece. Olympic victor’s dark ointment (OVDO) 
mentioned by Galen (c. 129-200 CE), was an opium-based patch that was applied 
to the skin of athletes. It dried rapidly to cover a localised area and recent 
measurements of the transdermal transfer of morphine indicate a transfer 
comparable to 25% of modern transdermal patches.[97, 98] It may have, 
therefore, acted both systemically to reduce pain and by local effects, acting on 
inflammatory mechanisms. The Latin description for its use by Galen of 
Pergamum (130-200 CE) and its English translation states: 
                     Facit ad maximos Dolores - useful for extreme pain 
                    Nam ftatim liberat - providing relief immediately.[97] 
Perhaps this was an early indicator for a more recent and disgraceful practice in 
sport.   
The modern contemporary use of opioids as topical agents is somewhat marginal 
and is mainly confined to the management of skin and corneal ulceration, having 
some local anti-inflammatory actions.[99, 100] The increased expression of 
opioid receptors on nociceptors in inflammatory pain states provides a logical 
target for topically applied opioids. There are indications that topically applied 
opioids can ameliorate the pain of skin ulcers and post radiation mucositis [99, 
101-103], but the numbers in various clinical trials have been low and further 
evidence is needed.  Their usage is perhaps best seen in the palliative care field 
where they can relieve inflammatory pain without significant systemic side 
effects.[99] Topically applied morphine can be applied in gels and oral rinses 
prepared by pharmacies over a range from 0.1-2% concentration.[104, 105] 
Other opioids employed in topical applications include methadone [106], 
fentanyl [100], and oxycodone.[107] 
 
Mandragora: Employed as a topical analgesic agent and central sedative that is 
no longer used due to its toxic effects, mandragora (mandrake) has an ancient 
and fascinating history. Mandragora officinarum is native to the eastern 
Mediterranean and contains the active ingredients scopolamine and 
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atropine.[108] It has even been termed the “Anesthetic of the Ancients”.[109] It 
is mentioned in the Ebers papyrus as a sedative [4] and features in several 
hieroglyphic inscriptions.[109] Hannibal (247-182 BCE) used it to drug his 
opponents during the Battle of Carthage (200BCE).[110] Mentioned in the Bible, 
Genesis 30:14-24, mandrake subsequently achieved a reputation amongst 
medieval Christians for enhancing fertility. It was advocated in the writings of 
Flavius Josephus (c. 37-101) that a dog be employed to pull out the root, thus 
avoiding any lethal effects on humans from hearing the scream of the mandrake 
plant as it was pulled from the ground.[110] Mandrake also had demonic 
associations and was even used in the indictment of Joan of Arc in 1431 CE.[111] 
The use of mandrake most probably produced sufficient topical analgesia and 
sedation for the physician Hua Tuo (110-207 CE) to debride an arrow wound in 
General Guan Yu after the battle of Fan city but allowing him to continue playing 
chess, talk and laugh as if nothing had happened.[4] More recently, it featured in 
several of Shakespeare’s works, such as Cleopatra, act 1, scene v: “Give me to 
drink Mandragora-that I might sleep out this great gap of time. My Antony is 
away.” Mandragora was mixed with plant extracts such as opium and henbane 
(Hyoscyamus niger, another tropane alkaloid which can also be applied topically 
for “obstinate rheumatic pains”), to produce sedation for surgical procedures. It 
was evaporated into a sea sponge and the preparation known as Spongia 
somnifera was employed extensively until its use faded with the advent of 
general anaesthesia in the nineteen century CE.[109, 112] The potency and 
toxicity of this plant extract varied considerably depending on its mode of 
extraction. With no attempt at purification or precise dosing, Spongia somnifera 
could cause death from respiratory and circulatory depression.[113] 
 
Cocaine: Topical local anaesthetic agents currently play a significant part in 
treating some neuropathic pain conditions. Cocaine derived from coca leaves, 
Erythroxylum coca was first used as a topical local anaesthetic agent on the 
cornea of a frog and then a human by Karl Koller in 1884, after discussions with 
his friend Sigmund Freud, who was interested in cocaine for its effects on his 
patient’s mood.[114] The origins of coca are ancient, however, dating back to the 
pre-Moche period (100-750 CE) in Peru and the Eastern Andes. The coca leaf 
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was chewed or used to make tea to combat fatigue and altitude sickness. Traces 
of coca have been found in mummified human cadavers dating back 3000 years 
[115] and probably millennia before this. The French naturalist Joseph de Jussieu 
(1704-1779) introduced coca leaf into Europe, and cocaine was isolated from the 
mix of alkaloids from the coca plant by Gaedecke in 1855 who called it 
Erythroxyline and subsequently extracted and purified by Niemann in 1860. It 
became popular as a stimulant in the 19th century CE and was even included as 
an ingredient in early formulations of Coca-Cola until 1903 when it was 
withdrawn.[116] Cocaine’s addictive qualities were recognised in the nineteenth 
century and it became a widely prohibited substance in the early 20th century CE. 
The use of unprocessed coca leaves is still lawful in some South American 
countries. 
Local anaesthetic agents have become one of the mainstays of modern surgery. 
Topical local anaesthetic agents are also finding a place in the management of 
some pain states, in particular neuropathic pain. The use of a 5% lidocaine patch 
to treat neuropathic pain states, especially post herpetic neuralgia, has received 
particular attention and is the subject of several reviews.[117-119] The use of a 
lidocaine patch has also been the subject of a 2008 Cochrane review, which 
concluded that three studies into its efficacy had sufficient scientific rigour to be 
included but provided insufficient evidence to support its use as a first-line 
treatment of post herpetic neuralgia.[120] More recent reviews would suggest 
otherwise. For example, a review by Wolff et al. concluded that a 5% lidocaine 
topical patch is more effective than capsaicin and pregabalin.[119] Lidocaine has 
also been used as a topical spray for dressing changes, for pain associated with 
peripheral blood flow disorders, and post herpetic neuralgia.[121-123] Safety 
issues have been considered in a 2002 pharmacokinetic study that considered 
the 5% lidocaine patch to be safe, only causing mild skin erythema and low 
plasma lidocaine levels [124], but a single case report has concluded that 
lidocaine toxicity is possible when multiple forms of topical application are 
used.[125] 
 
Topical non-steroidal anti-inflammatory drugs (NSAIDs): Extracts from 
willow trees and other salicylate containing plants also have their origins in 
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antiquity, possibly dating back to the Sumerians and ancient Egyptians in the 
treatment of fevers. The active ingredient, acetylsalicylic acid (aspirin) was 
synthesised by the Bayer Company in 1897.[126] Salicylates are largely 
administered orally but there has been some topical use of aspirin containing 
solutions of chloroform or ether in the treatment of post herpetic neuralgia.[127] 
Modern NSAID use commenced with the introduction of indomethacin in 
1962.[128] Significant gastrointestinal adverse effects from the oral 
formulations of NSAIDs have been encountered and in an effort to reduce these 
effects, various topical preparations of NSAIDs have been developed. In a recent 
comprehensive review of these topical preparations, it was concluded that 
topical NSAIDs were superior to placebo and had similar outcomes to oral 
NSAIDs in the treatment of both acute and chronic musculoskeletal injuries.[129] 
Gastrointestinal side effects were less with the topical group but minor skin 
reactions were more frequent. Several formulations, discussion concerning 
penetration enhancers and guidelines for use have been published regarding this 
group of topical agents.[126, 130-132] Topical versus oral NSAIDs can be 
particularly advantageous in the elderly and have been recommended as a first-
line treatment for osteoarthritis in this age group.[133] 
 
Topical Agents of the Modern Era: amitriptyline, clonidine and ketamine: 
Amitriptyline, a tricyclic antidepressant, has a number of actions including its 
ability to inhibit the reuptake of noradrenaline and serotonin. It has been shown 
to block various voltage gated ion channels including Na+, K+ and Ca++ [134,135] 
and several receptors including α2 adrenoceptor, cholinergic, NMDA and 
histamine [134-136] pointing to a use as a topical agent with peripheral nerve 
fibre effects.[137] Although not effective in every trial [138], amitriptyline at 
concentrations between 2-10%, along with some other antidepressant agents 
has been successfully used as a topical agent in a number of neuropathic pain 
states including complex regional pain syndrome (CRPS), multiple sclerosis and 
vulvodynia.[139-141] Amitriptyline has been employed as a sole agent or in 
combination with other topical agents such as ketamine and baclofen.[142-147] 
Although the topical application of antidepressant drugs can reduce their 
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unwanted central side effects, this form of administration can occasionally lead 
to adverse toxicity.[148] 
Clonidine is an α2-adrenergic receptor agonist used in the treatment of 
hypertension. Side effects that include somnolence and hypotension have limited 
its use in treating neuropathic pain states. It has, however, been found to be 
antinociceptive if applied to the skin and successfully used in the reduction of 
hyperalgesia in patients with sympathetically maintained pain [149] and painful 
diabetic neuropathy.[150] Blood levels of clonidine in this later RCT were below 
the level of detection suggesting that the effects of this topical agent were 
peripherally mediated and probably a direct effect on epidermal nociceptors. 
Typically, it is applied as a patch (30mcg/cm2/day) or as a 0.1-0.2% solution. 
Ketamine, which blocks glutamate N-methyl-D-aspartate (NMDA) receptors on 
peripheral nerve fibres, can reduce nociceptive transmission.[151] It has been 
studied as a topical analgesic agent and has been the subject of many trials, case 
reports and reviews.[152-154] It can be used as a gel or cream with relative 
safety and apparent efficacy mainly for localised neuropathic pain states at 
concentrations up to 20%.[153] There have also been a number of reports of its 
use in combination with other agents such as amitriptyline, baclofen and 
gabapentin but with mixed results.[141, 142, 147] Long-term effects on the 
urinary tract [155] may be circumvented by the use of topically applied 
ketamine, which results in low plasma levels of the drug.[156] Nevertheless, as 
with some other topical drugs, inappropriate or excessive use can lead to 
significant toxicity.[157] 
Combinations of drugs for topical application can be used for treatment of some 
pain states -for example: ketamine 10% with amitriptyline 4% in Vanpen® 
penetrant for post herpetic neuralgia or amitriptyline 2-4% combined with 
gabapentin 6-10% with oestradiol 0.01% for vulvodynia are used in clinical 
practice but the rationale for the selection of agents, their percentage 
composition and the vehicle used is not clear. A recent review by Zur 2014 
considers such mixtures in depth.[62] Such tailored recipes are controversial 
and can attract the criticism of being entrepreneurial.  
 
Conclusion and Future Perspectives 
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A number of substances have been applied to the skin and mucosa for painful 
conditions over thousands of years but without any understanding of their 
pharmacological actions. The inevitable toxic effects of some substances have led 
to their withdrawal from use. Others seen to have beneficial effects continue to 
be applied to this day, but with considerable refinement in their use and 
understanding of the mechanisms involved. As the knowledge of peripheral pain 
pathways has increased, so has the tailoring of drugs to act on these mechanisms 
of nociception. After penetration of the skin they are able to act directly on the 
initiating factors that lead to pain. Most advantageously, the use of topical drugs 
has reduced the adverse effects of many of these agents that are also 
administered systemically.  This can be of great benefit to the frail and elderly.  
The future for the topical application of drugs is bright. In addition to improved 
targeting of specific pain mechanisms with new drugs or different formulations 
of existing ones, enhanced penetration agents will improve delivery of these 
agents. “Topicals” prepared in laminar flow facilities will allow application to 
areas of broken skin or mucosa without encouraging infection. Alternative 
routes for topical applications of drugs will be developed including the rectal 
mucosa, vulva and the oropharynx. Lastly, as best practice for topical drug 
application becomes clearer from a pharmacological perspective, so will the 
selection of suitable patients and pain states that are likely to respond.  
 
Executive Summary: 
• The topical application of drugs that act locally in the skin provides an 
attractive strategy for treating pain, reducing the potential systemic side effects 
of oral or parenteral administration. 
• Some agents used since antiquity have been discontinued but others are used 
to this day. 
• Mechanisms of action include effects on skin neural networks and 
inflammatory processes. 
• The stratum corneum layer of the skin presents a significant barrier to the 
absorption of drugs. Penetration enhancers have evolved that improve this 
absorption. 
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• Menthol, used in ancient Egypt, is experiencing a renaissance. Acting on the 
TRPM8 receptor, it imparts a cool sensation to the skin and mucosa. 
• Capsaicin, acting on the TRPV1 receptor, also has an ancient lineage being 
derived from chilli peppers. It imparts a sensation of heat to the skin and 
mucosa. 
• Opioids, described for topical use for athletes in ancient Greece, have more 
recently been employed in the treatment of painful skin and corneal ulceration. 
• Mandragora (Mandrake) is a topical plant extract with a long history of use 
that has been discontinued due to its unpredictable toxicity.  
• Local anesthetic agents discovered in the nineteenth century, have their origin 
in cocaine from the Americas. The 5% lidocaine patch has some utility in 
treating neuropathic pain states such as post herpetic neuralgia. 
• The use of topical NSAIDS follows in the footsteps of the application 
salicylate containing plants by ancient Sumerians and Egyptians. Topically 
applied NSAIDs show efficacy in the treatment of painful musculoskeletal 
structures comparable to oral ingestion but without the gastro-intestinal side 
effects. 
• Topical amitriptyline, clonidine and ketamine are examples of modern topical 
agents, employed principally for neuropathic pain, that are supported by a 
significant literature. 
• The future for topical drugs is encouraging, as the mechanisms of pain have 
become better understood. The development of new topical preparations, 
penetration enhancers and sterile techniques of preparation have all 
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Illustration: Human Skin: A section of normal human skin demonstrating the 4 
principal layers. Nerve fibres (green), including nociceptors have been stained by 5 
PGP9.5, which is a pan neuronal immunohistochemical marker. (From 6 
unpublished work by Finch P and Drummond D) 7 
